Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations

Ching Kuo Tan
Gui Quan Say
James B Geake
Department of Respiratory Medicine, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia

Abstract: Tiotropium bromide is a long-acting inhaled muscarinic antagonist used in patients with chronic respiratory disease. It has been available since 2002 as a single-dose dry powder formulation via the HandiHaler® dry powder inhaler (DPI) device, and since 2007 as the Respimat® SoftMist™ Inhaler (SMI). The latter is a novel method of medication delivery that utilizes a multidose aqueous solution to deliver the drug as a fine mist. Potential benefits include more efficient drug deposition throughout the respiratory tract, reduced systemic exposure, and greater ease of use and patient satisfaction compared with the use of HandiHaler DPI. Although tiotropium bromide delivered via the HandiHaler DPI has been clearly shown to improve lung function, dyspnea, and quality of life and to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), there is accumulating evidence regarding the use of tiotropium HandiHaler in other respiratory diseases characterized by airflow limitation, such as asthma and cystic fibrosis. Developed more recently, tiotropium delivered via the Respimat SMI appears to have a similar efficacy and safety profile to the HandiHaler DPI, and early data raising the possibility of safety concerns with its use in COPD have been refuted by more recent evidence. The benefits over the HandiHaler DPI, however, remain unclear. This paper will review the evidence for tiotropium delivered via the Respimat SMI inhaler, in particular as an alternative to the HandiHaler DPI, and will focus on the safety profile for each of the chronic lung diseases in which it has been trialed, as well as an approach to appropriate patient selection.

Keywords: tiotropium, Respimat, safety, COPD, asthma, HandiHaler

Introduction

Tiotropium bromide (Spiriva®, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany) is an inhaled long-acting muscarinic antagonist. It acts via competitively binding predominantly to M3 receptors contained within bronchial smooth muscle, attenuating cholinergic-mediated bronchoconstriction.1

It was approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of chronic obstructive pulmonary disease (COPD) via the HandiHaler® dry power inhaler (DPI, Boehringer Ingelheim International GmbH),2 and has subsequently been approved across many health care jurisdictions worldwide for this indication. There is convincing evidence that this treatment results in improved lung function and quality of life and reduced breathlessness and exacerbations in patients with COPD.3–6

It has also been trialed in other obstructive lung diseases, and in particular there is now also increasing evidence that it has favorable effects on chronic suboptimally controlled asthma.7–9 The HandiHaler DPI device delivers tiotropium via an inhaled dry powder mechanism, using lactose powder as a carrier.10 This mechanism relies...
on the inspiratory airflow generated by the patient to deposit the drug particles in the lungs. Many variables influence the amount of drug inhaled into the lungs, including inspiratory flow profile of the device, inspiratory airflow volume generated by the patient, and the amount of moisture in the oropharynx. Therefore, it is possible that drug deposition varies considerably between patients and is likely to be compromised in patients who have severe respiratory disease with already limited inspiratory capacity.

In attempts to improve drug deposition, particularly for patients with severe chronic lung disease who are unable to generate sufficient inspiratory flow rates, the Respimat® SoftMist™ Inhaler (SMI; Boehringer Ingelheim International GmbH) was developed. It was approved by the FDA in September 2014 and dispenses a 5-μg dose. In this novel delivery device, mechanical energy (via a spring that is actuated by the patient) is used to convert a liquid drug solution to a transient mist, which can then be inhaled by the patient. This means that the delivered drug dose is independent of inspiratory effort, and the increased time for which the drug remained in the oropharynx provided greater opportunity to coordinate device actuation and patient inhalation. In addition, the Respimat SMI inhaler results in high fine-particle fraction, as well as low ejection velocity and long spray duration. In combination, it is postulated that these features provide improved lung deposition, minimize loss of small diameter particles during exhalation, and reduce oropharyngeal deposition. Supporting evidence comes predominantly from trials using compounds other than tiotropium, in healthy patients without lung disease or in patients with mild-to-moderate asthma. The extent to which these theoretical benefits translate into improved clinical efficacy and acceptable safety profile remains controversial.

**Search strategy**

We performed a literature search from the databases Medline and Cochrane Library, with the assistance of an experienced librarian. The search terms and study flow diagram are included in the supplementary material (Table S1 and Figure S1).

**Pharmacokinetics and pharmacodynamics**

Tiotropium is an anticholinergic agent. Upon delivery to respiratory epithelium, it competitively and reversibly binds as an antagonist to the M3 subtype muscarinic receptors within bronchial smooth muscle, resulting in bronchodilation because of inhibition of cholinergic-mediated bronchoconstriction. As with any inhaled medication, not all of the dispensed medication reaches the intended airway mucosa. A proportion is lost through exhalation or coughing, and a portion is delivered directly to the systemic circulation after deposition in the upper aerodigestive tract. In vitro studies suggest that tiotropium does not undergo significant hepatic metabolism and is predominantly cleared by renal action. It is the small proportion of active drug reaching the systemic circulation that is responsible for many of the unwanted side effects of the drug, and therefore lower systemic exposures might be expected to result in fewer adverse and serious adverse events. Thus, the lower dose of tiotropium dispensed with Respimat SMI, in combination with a possible greater efficiency of delivery, might result in a reduction in systemic exposure, and in turn an improved safety profile.

However, pharmacokinetic data from clinical trials have been conflicting. Some have shown generally similar profiles, others have suggested increased systemic exposure with the Respimat SMI, and still others have more recently demonstrated the opposite. In 2014, a crossover trial enrolled 154 COPD patients who were then randomized into five different treatment arms comprising placebo, tiotropium HandiHaler DPI 18 μg, and tiotropium Respimat SMI 1.25, 2.5, and 5 μg, respectively. This study found lower peak plasma concentrations (C_max) in the tiotropium Respimat SMI 5-μg solution group compared to the HandiHaler DPI group (Figure 1), although it was still greater than in the manufacturer’s report. On the other hand, plasma concentrations of tiotropium HandiHaler DPI were significantly less in pharmacological studies compared to the manufacturer’s reported value. Given the conflicting pharmacokinetic data, in vitro bioequivalence cannot be assumed between the HandiHaler and Respimat devices.

**Tiotropium Respimat SMI in asthma**

**Efficacy**

There is now an accumulating and reasonably substantial body of evidence supporting the use of tiotropium Respimat SMI in patients with suboptimally controlled asthma despite optimal treatment with moderate-to-high doses of inhaled corticosteroids (ICS), either in addition to ICS/long-acting β-2-agonist (LABA) combination, or in place of a LABA. Kerstjens et al was one of the first to demonstrate its benefit in a randomized controlled trial conducted in 2011, where they found significant spirometric and clinical benefits of tiotropium Respimat SMI compared to placebo. Since then, many other studies have shown similar results (Table 1).
Perhaps more importantly, tiotropium Respimat SMI was shown to reduce the risk of asthma exacerbations compared to placebo, even with the use of adjunct therapies. Overall, tiotropium Respimat SMI has been shown to be beneficial in patients with asthma, regardless of age, baseline function, allergic status (as defined by serum Immunoglobulin E levels, or clinical evidence of allergic asthma), or phenotype. There are no studies that directly compare the efficacy between tiotropium HandiHaler DPI and tiotropium Respimat SMI in patients with asthma.

Safety and tolerability

Tiotropium Respimat SMI appears to be generally well tolerated in patients with asthma, and rates of discontinuation reported in clinical trials have been low (between 1% and 4%). Fatal events have been extremely rare, and no mortality signal to match the early concerns in the COPD population has emerged. However, the frequency of adverse events, in particular severe adverse events, does appear to increase with increasing doses of tiotropium. A large pooled analysis found that patients who are administered 5 μg tiotropium Respimat SMI are 1.5 times more likely to have an adverse event leading to discontinuation, and 2.28 times more likely to have a severe adverse event compared to those who receive 2.5-μg tiotropium Respimat SMI. Similarly, patients who are administered 10-μg tiotropium Respimat SMI are 1.15 times more likely to experience an adverse event compared to patients who are given 5-μg tiotropium Respimat.
Table 1 Summary of studies comparing the efficacy of tiotropium Respimat SMI in patients with asthma

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comparison/intervention</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fardon et al⁶⁰</td>
<td>Randomized, double-blinded, placebo-controlled trial of 4 weeks duration, 26 asthmatic patients (mean age 54) with FEV₁ ≤65%</td>
<td>Tiotropium HandiHaler DPI 18 µg or placebo. Concomitant therapy: fluticasone (500 µg) and salmeterol (100 µg).</td>
<td>Significant improvement in FEV₁, and FVC. No significant changes in mini AQLQ score.</td>
</tr>
<tr>
<td>Peters et al¹¹</td>
<td>Randomized double-blind, crossover trial of 14 weeks duration, 210 patients, mean age 42, baseline FEV₁ 71.5% predicted.</td>
<td>Beclomethasone 160 µg, beclomethasone 80 µg plus tiotropium HandiHaler DPI 18 µg, beclomethasone 80 µg plus salmeterol 50 µg.</td>
<td>Patients receiving salmeterol and tiotropium as an adjunct therapy had significantly improved PEFR, FEV₁, ACQ, and AQLQ scores compared to beclomethasone monotherapy. Tiotropium was noninferior to salmeterol and both were superior to placebo in terms of morning PEFR improvement. Better asthma symptom-free days with tiotropium compared to salmeterol. Tiotropium Respimat SMI improves FEV₁ and AQLQ scores compared to placebo. No significant differences between different doses of tiotropium Respimat SMI. Similar safety profile across all groups. Tiotropium Respimat SMI and salmeterol improves FEV₁ (peak), FVC, and PEFR compared to placebo. Intergroup comparison was not made. ACQ score: significant improvement in Tio R2.5 and salmeterol, but both had an MCID of &lt; 0.5. Slightly higher adverse events in Tio R2.5 group (63.4%) compared to others (56.4%-56.7%). Significant improvement in peak FEV₁, FVC, PEFR, and ACQ score across all doses of tiotropium Respimat SMI and salmeterol versus placebo. Intergroup comparison not performed. Similar adverse events between all groups. Significant improvement in FEV₁ in both Tio R2.5 and Tio R5 compared to placebo. Significant improvement in FVC observed in only Tio R2.5 group. No improvement in ACQ scores. Adverse events were similar across all groups. Tiotropium increased time to first asthma worsening (risk reduction, 31%; HR = 0.69; P &lt; 0.001). All three doses produced statistically significant improvements in FEV₁ and FVC compared to placebo. No spirometric differences between each treatment group were observed. Less adverse events in the Tio R1.25 group compared to higher-dose arms. Significant improvement in peak FEV₁ (peak) in all treatment groups compared to placebo. No improvements in FVC or ACQ scores. Similar adverse events across all groups.</td>
</tr>
<tr>
<td>Bateman et al⁹⁰</td>
<td>Randomized, double-blinded trial of 16 weeks duration, 388 asthmatic patients with positive Bl 6 Arg/Arg phenotype, aged 18–67.</td>
<td>Tio R5 + placebo salmeterol or 50 µg salmeterol + tiotropium placebo.</td>
<td></td>
</tr>
<tr>
<td>Kerstjens et al²³</td>
<td>Randomized, double-blinded crossover trial of 8 weeks duration, 107 patients with suboptimally controlled asthma randomized, mean age 55, mean FEV₁ 58% predicted.</td>
<td>Tio R5, Tio R10, or placebo. Concomitant therapy: high-dose ICS and LABA.</td>
<td></td>
</tr>
<tr>
<td>Kerstjens et al⁶²</td>
<td>Phase III randomized, double-blind, placebo, controlled, parallel group trial of 24 weeks duration, 1,030 patients, mean age 42, baseline FEV₁ 75.4% predicted. Parallel trial to BI 205.418.</td>
<td>Tio R2.5, Tio R5, salmeterol, placebo. Concomitant therapy: medium-dose ICS (regime not specified).</td>
<td></td>
</tr>
<tr>
<td>BI205.418 (NCT01172808)</td>
<td>Phase III randomized, double-blind, placebo, controlled, parallel group trial of 24 weeks duration, 1,071 patients, mean age 43, baseline FEV₁ 77.6% predicted. Parallel trial to BI 205.419.</td>
<td>Tio R2.5, Tio R5, salmeterol, placebo. Concomitant therapy: medium-dose ICS (regime not specified).</td>
<td></td>
</tr>
<tr>
<td>Pagliaro et al¹⁴</td>
<td>Phase III, randomized, double-blind, placebo-controlled, parallel group trial of 12 weeks duration, 310 patients, mean age 42, baseline FEV₁ 77.6% predicted.</td>
<td>Tio R2.5, Tio R5, placebo. Concomitant therapy: low-dose ICS (regime not specified).</td>
<td></td>
</tr>
<tr>
<td>Kerstjens et al³⁴</td>
<td>Subgroup analysis of data from PrimoTinA-asthma trials of 48 weeks duration, 912 patients, mean age 53, baseline FEV₁ 55% predicted.</td>
<td>Tio R5 or placebo. Concomitant therapy: ICS (dose regime not specified) and LABA.</td>
<td></td>
</tr>
<tr>
<td>Beeh et al²⁷</td>
<td>Randomized, double-blinded crossover trial of 4 weeks duration, 149 patients randomized, mean age 49, baseline FEV₁ 71.3% predicted.</td>
<td>Tio R1.25, 2.5, 5, placebo. Concomitant therapy: 400–800 µg budesonide equivalent ICS.</td>
<td></td>
</tr>
<tr>
<td>BI 205.444 (NCT01257230)</td>
<td>Phase III, randomized double-blind, placebo, controlled, parallel group study, 398 patients, mean age 14, baseline FEV₁ 82.8% predicted. Trial duration 48 weeks.</td>
<td>Tio R2.5,5, placebo. Concomitant therapy: medium dose ICS (regime not specified).</td>
<td></td>
</tr>
</tbody>
</table>
**Therapeutic and Clinical Risk Management**

**Phase III, randomized double-blinded, parallel group study**

- **Vogelberg et al.**
  - Randomized, double-blinded, multicenter, crossover trial of 4 weeks duration, 105 patients, mean age 14 years, baseline FEV1, 77.5% predicted.
  - Tio R1.25, 2.5, 5 µg, placebo.
  - Concomitant therapy: medium-dose ICS.
- **Wolfgang et al.**
  - Randomized double-blinded crossover trial, 99 patients, mean age 44 with moderate or severe asthma. Trial duration 15 weeks.
  - Tio R2.5, 5, placebo.
  - Concomitant therapy: 400–800 µg budesonide equivalent ICS.
  - Significant improvement in FEV1 and PEFR in Tio R5 group of 4 weeks duration, 105 patients, mean age 45, baseline FEV1 80% predicted. Trial duration 12 weeks.
  - Similar adverse events across all groups.
- **Oh et al.**
  - Phase III, randomized double-blinded, parallel group study of 52 weeks duration, 285 patients, mean age 45, baseline FEV1 77.5% predicted.
  - Tio R2.5, 5, placebo.
  - Concomitant therapy: medium-dose ICS (regime not specified).
  - Significant improvement in FEV1, PEFR, and ACQ-7 scores in all treatment groups compared to placebo. No significant difference in any outcome between treatment groups. Higher adverse events in Tio R5 group compared to placebo group. No difference in outcomes between treatment groups.

**Concomitant therapy:**
- Medium-dose ICS.
- 400–800 µg budesonide equivalent ICS.

**Tio R1.25, 2.5, 5, placebo.**

**Patient selection and special considerations**

In most guidelines, tiotropium is suggested for asthmatic patients with persisting evidence of disease activity as measured by lung function or symptom records, with increasing doses of tiotropium, often excluded. Given the small increase in adverse events with increasing doses of tiotropium, caution should be exercised before prescribing tiotropium in patients with poorly controlled asthma. They found that while tiotropium confers spirometric improvement, it has been associated with a decrease in exacerbations and improvement in asthma control. A meta-analysis conducted in 2015 found that the benefit of tiotropium is greatest in patients with poorly controlled asthma. The American Thoracic Society guidelines recommend adding tiotropium to medium- or high-dose ICS (200–800 µg of beclomethasone equivalent) plus long-acting β2-agonist therapy (Figure 2). The GINA guidelines recommend adding tiotropium if an adult patient's symptoms are not controlled by medium- or high-dose ICS (Global Initiative for Asthma) guidelines recommend adding tiotropium and LABA to existing therapy regimes, as it has been shown to improve outcomes in patients with persisting evidence of disease activity, despite the use of high-dose ICS. Such recommendations are corroborated by the manufacturer’s recommendations for tiotropium. Adverse events are rare, ranging from 0.4% to 4%, and if symptoms are not controlled by tiotropium should be increased, considering the American Thoracic Society guidelines for the use of long-acting muscarinic antagonists should be reserved only for moderate-to-severe asthma. The most common adverse events are nasopharyngitis and upper respiratory tract infection. Coronary artery disease was also reported in 0.8% of cases. The most common severe adverse events are pancreatitis and cardiac arrhythmias. The most common severe adverse events are pancreatitis and cardiac arrhythmias. The most common severe adverse events are pancreatitis and cardiac arrhythmias. The most common severe adverse events are pancreatitis and cardiac arrhythmias. The most common severe adverse events are pancreatitis and cardiac arrhythmias.
Tiotropium Respimat SMI in COPD

Efficacy

Tiotropium HandiHaler DPI 18 µg improves lung function, dyspnea, and quality of life and reduces exacerbations in patients with COPD. There is now a fairly large volume of accumulated data demonstrating similar spirometric and clinical outcomes between the HandiHaler DPI and the Respimat SMI. Both direct randomized placebo-controlled trials comparing Respimat SMI with placebo and noninferiority trials comparing Respimat SMI with HandiHaler DPI support their use in stable COPD.

Safety and tolerability

Dry mouth, constipation, and urinary tract infections are the most commonly reported adverse events in patients with COPD. The most common nonanticholinergic-mediated adverse events were nasopharyngitis, sinusitis, bronchitis, and exacerbations of COPD. Other less common side effects (<1%) include urinary retention, dry skin, angioedema, abnormal liver function test, and gastroesophageal reflux disease.

For several years, there were concerns regarding the safety of tiotropium Respimat SMI. Although many of the original trials showed no significant deaths or adverse events, initial aggregate data raised the possibility of a safety signal for Respimat SMI. In particular, two systematic reviews reported an increase in mortality with the Respimat SMI device. Shortly thereafter, a population-based longitudinal observational study was done in the Netherlands that showed an increased risk of death in patients using Respimat SMI compared to HandiHaler DPI, and that the risk was higher in patients with coexisting cardiovascular disease. Critiques pointed out that the reviews described earlier were confounded by imbalances in the randomization and higher dropouts in the placebo group, and the inclusion of the Respimat SMI 10 µg dose. Nonetheless, in the light of these findings, the FDA initially did not approve the use of tiotropium Respimat SMI in the USA.

The TIOSPIR study was conducted with the primary aim of addressing this concern and directly compared Respimat SMI and HandiHaler DPI in patients with COPD. This large double-blind study involved a total of 17,135 patients with COPD who were treated for a median duration of 835 days and followed up for a median of 2.3 years. The patients were randomized to receive either Respimat SMI 2.5 µg or Respimat SMI 5 µg, or a tiotropium HandiHaler DPI. Mortality rates were similar between tiotropium Respimat SMI 2.5 µg or 5 µg and tiotropium HandiHaler DPI (7.7% death from any cause in the Respimat SMI 2.5-µg group, 7.4% death in the Respimat SMI 5-µg group, and 7.7% in the HandiHaler...
DPI group). There was also no significant difference in cardiovascular deaths between the groups. In light of these data, the FDA approved tiotropium for use in stable COPD, and it has now been accepted for this indication across a number of health care jurisdictions around the world. It is important to note that although patients with concomitant cardiac disease were included, the patients with more acute cardiac disease were excluded from the trial (myocardial infarction within 6 months, NYHA Class III and IV heart failure admissions within 12 months, and unstable arrhythmias). Patients with unstable COPD were also excluded from the trial (recent exacerbation within 4 weeks, awaiting surgical intervention, and chronic use of corticosteroids >10 mg/d of prednisolone). They also excluded patients with other significant lung diseases (interstitial lung disease, bronchiectasis, asthma, cystic fibrosis [CF], or pulmonary thromboembolism). Finally, a stratified analysis of patients with and without chronic renal impairment from a partial cohort of the TIOSPIR study also demonstrated an increase in mortality associated with the use of tiotropium Respimat SMI in patients with Stage 3 to 5 chronic renal impairment, compared to placebo (adjusted hazard ratio [HR] = 1.52, 95% confidence interval [CI] = 1.02–2.28). Therefore, there is limited evidence to support the use of tiotropium Respimat in patients with other concurrent nonasthmatic pulmonary pathologies, or with significant renal impairment. Table 2 summarizes the studies comparing the efficacy profile of tiotropium Respimat SMI compared to HandiHaler DPI and/or placebo in patients with COPD.

Patient selection and special considerations

Overall, the data suggest fairly similar efficacy and safety profiles between Respimat SMI and HandiHaler DPI. Therefore, Respimat SMI should be considered for use in patients with stable COPD who are symptomatic or who suffer exacerbations. The use of both the devices should be carefully considered in patients with severe concomitant heart disease or other relative contraindications. However, there may be specific factors for patients with COPD that influence the use of one device over the other. Trotta et al conducted a retrospective, cohort, drug-utilization study to investigate factors that influence prescribers and patients to use tiotropium Respimat SMI or HandiHaler DPI. The study, conducted in 2011 in Italy, involved 9,920 COPD patients in a general hospital outpatient clinic, aged over 45 years with at least one prescription of tiotropium over a 2-year period. The researchers’ objectives were 1) to investigate what factors influence clinicians to prescribe a particular tiotropium formulation and 2) to investigate what factors led patients to switch from one formulation to another. They found that the HandiHaler DPI formed the majority (79.5%) of first prescriptions of tiotropium to patients; patients with underlying cardiac and neurological disorders were more likely to receive Respimat SMI as their first tiotropium prescription (odds ratio [OR] = 1.29–1.65, respectively). When evaluating “switchers”, only 5.4% of the patients in the total cohort switched to the Respimat SMI formulation during the 2-year period, and 67% of the switches happened within the first 60 days of being prescribed HandiHaler DPI. The factors that were identified in increasing predisposition to switching from HandiHaler DPI to Respimat SMI are underlying cardiac disease (OR = 1.76), severe respiratory disease requiring three (OR = 1.96) or more (OR = 4.62) other respiratory medications, and a younger age (OR = 1.92).

Therefore, at present, patient and clinician preferences, as opposed to evidence from clinical trials, are likely to be the greatest drivers with regard to device choice in COPD, and the relatively high proportion of patients on HandiHaler DPI and the relatively low number of switchers in the aforementioned study suggest that the HandiHaler DPI remains popular among clinicians and patients alike. However, there may be niche roles for Respimat SMI, for example, in people with neurological disease who may have difficulty coordinating the steps in preparing and actuating the HandiHaler DPI device. Notably, there are a number of alternative antimuscarinic antagonists entering the market worldwide, and in at least one patient-preference study, both the HandiHaler DPI and Respimat SMI performed worse than alternatives.

In conclusion, tiotropium Respimat SMI 5 μg appears to be efficacious and well tolerated when used in a selected COPD population. However, it should be used with caution in patients with COPD who have the following: a history of recent myocardial infarction (within 6 months); unstable/life-threatening cardiac arrhythmia (requiring intervention within 12 months), hospitalization for cardiac failure (within 12 months); moderate-to-severe renal impairment; other concurrent pulmonary pathology, including but not limited to interstitial lung disease, bronchiectasis, asthma, CF, or pulmonary thromboembolism because of the design of the trials, which excludes patients with other concurrent lung diseases.

Tiotropium Respimat SMI in CF

Efficacy

Tiotropium delivered by the Respimat SMI has been trialed in patients with stable CF bronchiectasis, although to date its routine use is not supported by existing Phase III trials.
Table 2 Summary of studies comparing the safety and efficacy of tiotropium Respimat SMI in patients with COPD

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comparison/intervention</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bateman et al</td>
<td>Two randomized, double-blinded, parallel group study; 1,990 patients</td>
<td>Tio R5, R10, placebo.</td>
<td>Significant improvement in FEV1 and COPD exacerbation rate in both treatment groups compared to placebo; intertreatment group comparison not performed. Similar adverse events and death rates across all groups.</td>
</tr>
<tr>
<td>Ichinose et al</td>
<td>Randomized, double-blinded, double-dummy, two-way crossover study; 184</td>
<td>Tio R5 and placebo HandiHaler DPI placebo Respimat SMI and tiotropium 18-μg HandiHaler DPI.</td>
<td>Clinically and statistically significant improvement in mean trough FEV1 in treatment group (Tio R5 and HandiHaler DPI) compared to placebo. Similar adverse events across all four groups.</td>
</tr>
<tr>
<td>Singh et al</td>
<td>Meta-analysis of randomized controlled trials.</td>
<td>Tio R5 and Tio R10 versus placebo.</td>
<td>Statistically significant increase in mortality rate with Tio R5 (RR = 1.46, P = 0.04) and Tio R10 (RR = 2.15, P = 0.04) when compared to placebo.</td>
</tr>
<tr>
<td>Verhamme et al</td>
<td>Population-based longitudinal observational cohort study; 11,287 tiotropium users.</td>
<td>Tiotropium Respimat SMI versus HandiHaler DPI.</td>
<td>Tiotropium Respimat SMI was associated with an increased mortality risk (HR = 1.57 for all-cause mortality and 1.56 for cardiovascular and cerebrovascular mortality) compared to HandiHaler DPI.</td>
</tr>
<tr>
<td>Wise et al</td>
<td>Randomized, double-blinded, parallel group study; 17,135 patients</td>
<td>Tio R2.5, Tio R5, and tiotropium HandiHaler DPI.</td>
<td>Noninferiority in efficacy and adverse events across all groups.</td>
</tr>
<tr>
<td>Karner et al</td>
<td>Review of data collected from 22 randomized controlled trials; 23,309 patients with stable COPD.</td>
<td>Tiotropium versus placebo.</td>
<td>Increased mortality in tiotropium Respimat SMI compared to placebo (Peto OR = 1.47, 95% CI = 1.04–2.08).</td>
</tr>
<tr>
<td>Halpin et al</td>
<td>Poled safety analyses of data from 35 randomized, double-blinded, parallel group trials; 24,555 patients.</td>
<td>Tiotropium versus placebo.</td>
<td>Tiotropium has lower rates of adverse events compared to placebo. No statistically significant difference in rates of fatal adverse events (RR = 1.37, 95% CI = 0.93–2.00) but higher rates of cardiac arrhythmia (RR = 3.25, 95% CI = 1.23–8.60).</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; DPI, dry powder inhaler; FEV₁, forced expiratory volume in 1 second (percent predicted); HR, hazard ratio; OR, odd ratio; RR, relative risk; SMI, SoftMist™ Inhaler; Tio R(x), tiotropium Respimat SMI x μg, where x represents a tiotropium Respimat SMI dose; COPD, chronic obstructive pulmonary disease.
Although spirometric improvements have been noted in both children and adults, these data have not been corroborated in larger Phase III trials, nor have any differences translated in clinically relevant outcomes. Boehringer Ingelheim, in its prescribing information for UK prescribers, does not recommend the use of tiotropium Respimat SMI in patients with CF.

Safety and tolerability
There were no reported increase in adverse events across all three studies, and all of the studies demonstrated good tolerability of tiotropium Respimat SM, with low withdrawal rates. Adverse events were generally minor, with the most common being cough, pyrexia, and nasopharyngitis. However, Ratjen et al found a numerical, although not statistically significant, increase in the risk of infective exacerbations of CF in the tiotropium Respimat SMI group when compared to placebo. To the best of our knowledge, no studies have been performed to ascertain whether there is a similar signal with tiotropium HandiHaler DPI. There are no studies comparing the efficacy or safety of tiotropium Respimat SMI and HandiHaler DPI in patients with CF at the time of writing. Therefore, it is impossible to distinguish whether these observations might be related to the use of tiotropium itself, or the underlying delivery mechanism. However, it is possible the anticholinergic properties of tiotropium result in dehydration of airway secretions. Many of the inhaled treatments used in CF, which have been demonstrated to reduce exacerbations, work as airway hydrators, increasing the volume and composition of the airway surface liquid and improving sputum viscosity and airway clearance. Therefore, it is possible that the molecule itself may result in adverse outcomes such as exacerbations.

Patient selection
At present, the use of tiotropium via the Respimat SMI for patients with CF is not supported, in particular due to concerns around a possible increased risk of exacerbations of CF bronchiectasis. Although it is possible that this intervention might result in small spirometric improvements for some patients, given the relative paucity of robust data demonstrating clinical efficacy, combined with the aforementioned concerns around safety, Respimat SMI should not be recommended for patients with CF.

Conclusion
Tiotropium Respimat SMI appears to be efficacious, safe, and well tolerated in patients with asthma and COPD. Dose escalation beyond 5 μg has not been shown to improve spirometric or clinical outcomes, and in asthma, it has been associated with a small increase in adverse events. Although bioequivalence has not been convincingly demonstrated between Respimat SMI and HandiHaler DPI, clinical and spirometric outcomes appear comparable, at least for patients with COPD. There is no robust evidence that possible improvements in drug delivery result in improved clinical outcomes, and therefore selection of either the HandiHaler DPI or Respimat SMI should be made on a case-by-case basis, taking into account patient preferences, cost, individual patient tolerability, and potentially, the degree of impairment in lung function.

Most of the adverse effects of tiotropium Respimat SMI are consistent with its anticholinergic properties, for example, dry mouth and constipation. Importantly, early data suggesting an increase in mortality with Respimat SMI in COPD have not been corroborated in subsequent, large, well-conducted, head-to-head randomized controlled trials, and overall its use appears to be safe in COPD, where important contraindications have been excluded. Given the rigorous exclusion criteria from these clinical trials, tiotropium, delivered either via HandiHaler DPI or Respimat SMI, should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, severe renal impairment, and, particularly for Respimat SMI, those with cardiac rhythm disorders or recent myocardial infarction.

In patients with CF, the use of tiotropium Respimat SMI may increase the risk of infective exacerbations, and therefore its use for this indication cannot be supported at present.

In summary, tiotropium delivered via the Respimat SMI device has been shown to have similar efficacy and safety profile as the older HandiHaler DPI device in patients with asthma and COPD. Trials comparing the two devices failed to demonstrate superiority of one over the other; however, it remains a viable alternative to the traditional HandiHaler DPI.

Acknowledgments
The authors are grateful to Ms Wanda Pomeroy and the other librarians of Lyell McEwin Hospital, South Australia, for their assistance in performing the literature search.

Disclosure
The authors report no conflicts of interest in this work.

References


**Supplementary materials**

**Table S1** Search terms used in Medline and Cochrane

<table>
<thead>
<tr>
<th>Medline search strategy</th>
<th>Cochrane search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Tiotropium mp (1,219)</td>
<td>1. (Tiotropium and respimat and safety) mp [mp = ti, ot, ab, tx, kw, ct, sh, hw] (66)</td>
</tr>
<tr>
<td>2. Respimat mp (138)</td>
<td>2. Limit 1 to English language [Limit not valid in CDSR, ACP Journal Club, DARE, CLCMR; records were retained] (58)</td>
</tr>
<tr>
<td>3. Safety mp (369,568)</td>
<td>3. Limit 2 to year =&quot;2010–current&quot; [Limit not valid in DARE; records were retained] (53)</td>
</tr>
<tr>
<td>4. 1 – 3 (38)</td>
<td>4. Remove duplicates from 3 (51)</td>
</tr>
<tr>
<td>5. Remove duplicates from 4 (37)</td>
<td></td>
</tr>
<tr>
<td>6. Limit 5 to (English language and year =&quot;2010–current&quot;) (31)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CDSR, Cochrane Database of Systematic Reviews; ACP, American College of Physicians; DARE, Database of Abstracts and Review of Effects; CLCMR, Cochrane Methodology Register.

**Figure S1** Study flow diagram.